Analysts expect NovaBridge Biosciences to report revenue of 0.00 for 2026, against a range of 0.00 to 0.00. The most recent reported year, 2025, came in at 0.00.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 13.81 M | -32.17 M | 3.89 M | 0.00 | 0.00 | - | - | ||
| High Estimate | 81.47 M | 45.13 M | 4.10 M | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Low Estimate | 70.41 M | 40.12 M | 3.50 M | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Consensus Estimate | 75.94 M | 42.63 M | 3.80 M | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect NovaBridge Biosciences to report earnings per share of -0.64 for 2026, against a range of -0.70 to -0.58. The most recent reported year, 2025, came in at -0.21, a 75.0% miss against the -0.12 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -2.09 | -1.84 | -1.01 | -0.12 | -0.21 | - | - | ||
| High Estimate | -2.43 | -1.85 | -1.55 | -0.17 | -0.11 | -0.58 | -0.62 | ||
| Low Estimate | -2.77 | -2.23 | -1.87 | -0.19 | -0.13 | -0.70 | -0.72 | ||
| Consensus Estimate | -2.60 | -2.04 | -1.71 | -0.18 | -0.12 | -0.64 | -0.67 |
Pull Wall Street consensus for NovaBridge Biosciences (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NBP&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NBP", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NBP&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();